Pharmacokinetics and Biodistribution of the Antitumor Immunoconjugate, Cantuzumab Mertansine (huC242-DM1), and Its Two Components in Mice
- 1 March 2004
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 308 (3) , 1073-1082
- https://doi.org/10.1124/jpet.103.060533
Abstract
The humanized monoclonal antibody maytansinoid conjugate, cantuzumab mertansine (huC242-DM1) that contains on average three to four linked drug molecules per antibody molecule was evaluated in CD-1 mice for its pharmacokinetic behavior and tissue distribution, and the results were compared with those of the free antibody huC242. The pharmacokinetics in blood were similar for 125I-labeled conjugate and antibody with terminal half-lives of 154 and 156 h, respectively. Pharmacokinetic analysis using an enzyme-linked immunosorbent assay (ELISA) method, which measures intact conjugate in plasma samples revealed a faster clearance for the conjugate corresponding to a half-life of 42.2 h. This faster clearance is explained as the result of clearance from circulation and concomitant clearance of drug from circulating conjugate through linker cleavage. An antibody-specific ELISA allowed the determination of the clearance rate of the antibody component from circulation. The drug clearance rate from circulating conjugate was then calculated as the difference between the clearance of the conjugate and the clearance of the antibody component and found to be about three times that of the antibody component. The above results were confirmed with a conjugate, huC242-[3H]DM1, where the linked DM1 drugs carried a stable tritium label. Tissue distribution studies with 125I-labeled conjugate and antibody showed antibody-like behavior for the conjugate; the antibody of the conjugate did not distribute or bind significantly to any solid tissue.Keywords
This publication has 18 references indexed in Scilit:
- Scavenger endothelial cells of vertebrates: A nonperipheral leukocyte system for high-capacity elimination of waste macromoleculesProceedings of the National Academy of Sciences, 2002
- Finally! the Brambell receptor (FcRB)Immunologic Research, 1997
- Eradication of large colon tumor xenografts by targeted delivery of maytansinoids.Proceedings of the National Academy of Sciences, 1996
- Differential distribution of free and bound glutathione and cyst(e)ine in human bloodBiochemical Pharmacology, 1996
- Humanization of murine monoclonal antibodies through variable domain resurfacing.Proceedings of the National Academy of Sciences, 1994
- A fluorescent probe and a photoaffinity labeling reagent to study the binding site of maytansine and rhizoxin on tubulinBioconjugate Chemistry, 1993
- Removal of blood from laboratory mammals and birds: First Report of the BVA/FRAME/RSPCA/UFAW Joint Working Group on RefinementLaboratory Animals, 1993
- Biology and Diseases of MicePublished by Elsevier ,1984
- Chemical modification of ansamitocins. III. Synthesis and biological effects of 3-acyl esters of maytansinol.CHEMICAL & PHARMACEUTICAL BULLETIN, 1984
- Tumor inhibitors. LXXIII. Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatusJournal of the American Chemical Society, 1972